ELAB
Price
$1.58Alerts
Change
-$0.11 (-6.51%)
Updated
Nov 11 closing price
Capitalization
1.3M
2 days until earnings call
Intraday BUY SELL Signals
LXRX
Price
$1.87Alerts
Change
+$0.01 (+0.54%)
Updated
Nov 11 closing price
Capitalization
792.02M
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAB vs LXRX

ELAB vs LXRX Comparison Chart in %
View a ticker or compare two or three
VS
ELAB vs. LXRX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and LXRX is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ELAB with price predictions
Nov 10, 2026

ELAB in -4.24% downward trend, falling for three consecutive days on November 09, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ELAB declined for three days, in 229 of 236 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ELAB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELAB advanced for three days, in 76 of 91 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

ELAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.078) is normal, around the industry mean (3.498). P/E Ratio (-0.001) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.250) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. ELAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for LXRX with price predictions
Nov 10, 2026

LXRX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for LXRX turned positive on October 28, 2026. Looking at past instances where LXRX's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on LXRX as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.

LXRX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXRX advanced for three days, in 196 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 50-day moving average for LXRX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

LXRX broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LXRX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.538) is normal, around the industry mean (3.498). P/E Ratio (-11.125) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.570) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (19.120) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. LXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
LXRX: Fundamental Ratings
LXRX
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
18
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABLXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 23 days ago
84%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 13 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ELAB: $1.69 vs. LXRX: $1.86)
Brand notoriety: ELAB and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 666% vs. LXRX: 127%
Market capitalization -- ELAB: $1.3M vs. LXRX: $792.02M
ELAB [@Biotechnology] is valued at $1.3M. LXRX’s [@Biotechnology] market capitalization is $792.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 0 FA rating(s) are green while LXRX’s FA Score has 2 green FA rating(s).

  • ELAB’s FA Score: 0 green, 5 red.
  • LXRX’s FA Score: 2 green, 3 red.
According to our system of comparison, LXRX is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 4 TA indicator(s) are bullish while LXRX’s TA Score has 4 bullish TA indicator(s).

  • ELAB’s TA Score: 4 bullish, 2 bearish.
  • LXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ELAB is a better buy in the short-term than LXRX.

Price Growth

ELAB (@Biotechnology) experienced а -12.89% price change this week, while LXRX (@Biotechnology) price change was +27.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

ELAB is expected to report earnings on Nov 13, 2026.

LXRX is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ELAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with LPCN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
+6.96%
LPCN - ELAB
42%
Loosely correlated
-7.56%
LXRX - ELAB
25%
Poorly correlated
+2.20%
HURA - ELAB
25%
Poorly correlated
-9.04%
ERNA - ELAB
24%
Poorly correlated
-0.25%
MTNB - ELAB
24%
Poorly correlated
-0.81%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WTTR15.310.24
+1.59%
Select Water Solutions
NEXR2.130.01
+0.47%
Nexera Technologies Ltd
KRAQ10.040.02
+0.20%
Krakacquisition Corp
BMRN57.13-0.05
-0.09%
BioMarin Pharmaceutical
LNZA4.26-0.64
-13.06%
LanzaTech Global Inc